Atlantic International Corp. (ATLN)
Atlantic International Corp. is a life sciences instrumentation and research services company specializing in single-molecule DNA and RNA sequencing. Their True Single Molecule Sequencing (tSMS) technology platform caters to researchers in biomarker discovery and diagnostic assay development.
Company Overview
Atlantic International Corp. pioneers single-molecule sequencing with its tSMS platform, offering unparalleled accuracy and reproducibility for DNA and RNA analysis. Targeting the burgeoning fields of biomarker discovery and diagnostics, ATLN provides researchers with advanced tools for groundbreaking discoveries and personalized medicine.
Investment Thesis
Atlantic International Corp. presents a compelling investment opportunity within the rapidly evolving landscape of genomics and personalized medicine. The company's proprietary True Single Molecule Sequencing (tSMS) technology offers a distinct advantage in DNA and RNA analysis, driving demand from research institutions and pharmaceutical companies. With a market capitalization of $0.22 billion, ATLN is positioned for significant growth as the demand for accurate and reproducible sequencing data increases. Key value drivers include expansion of tSMS platform applications, strategic partnerships, and penetration into the diagnostic assay development market. The ongoing research and development agreements with the FBI and Weizmann Institute of Science serve as catalysts for innovation and validation of the tSMS platform's capabilities. Investors should consider ATLN for its disruptive technology and potential to revolutionize molecular diagnostics.
Key Highlights
- Market Cap of $0.22B reflects the company's current valuation and growth potential in the life sciences sector.
- Gross Margin of 10.9% indicates the profitability of the company's sequencing services and instrumentation sales.
- P/E Ratio of -1.86 suggests the company is not yet profitable, but reflects high growth expectations.
- Beta of 3.34 indicates high volatility, reflecting the speculative nature of the biotechnology industry.
- Research and development agreements with the FBI and Weizmann Institute of Science validate the tSMS platform's capabilities and potential applications.
Competitors
Strengths
- Proprietary True Single Molecule Sequencing (tSMS) technology.
- Research and development agreements with the FBI and Weizmann Institute of Science.
- Expertise in single-molecule sequencing and data analysis.
- Strong intellectual property portfolio.
Weaknesses
- Limited financial resources compared to larger competitors.
- Negative profit margin indicates current lack of profitability.
- High beta suggests high volatility and risk.
- Reliance on a single technology platform.
Catalysts
- Ongoing: Expansion of tSMS platform applications in biomarker discovery and diagnostic assay development.
- Ongoing: Strategic partnerships with pharmaceutical companies for drug discovery and development.
- Upcoming: Potential commercialization of forensic applications through the FBI partnership.
- Upcoming: Expansion into international markets, particularly in Europe and Asia.
- Ongoing: Continued research and development to enhance the tSMS platform's capabilities.
Risks
- Potential: Competition from established players in the sequencing market with greater resources.
- Potential: Technological advancements that could render the tSMS platform obsolete.
- Potential: Regulatory hurdles for diagnostic assay development and commercialization.
- Ongoing: Dependence on research funding and grants, which are subject to economic conditions.
- Ongoing: High volatility in stock price due to speculative nature of the biotechnology industry.
Growth Opportunities
- Expansion into Diagnostic Assay Development: Atlantic International Corp. can leverage its tSMS platform to develop and commercialize diagnostic assays for various diseases. The global diagnostic assay market is projected to reach $95 billion by 2028, presenting a significant growth opportunity for ATLN. By partnering with pharmaceutical companies and research institutions, ATLN can accelerate the development and adoption of its diagnostic assays.
- Strategic Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to utilize the tSMS platform for drug discovery and development can unlock substantial revenue streams. The pharmaceutical industry is increasingly relying on genomic data to identify drug targets and personalize treatment strategies. Atlantic International Corp. can position itself as a valuable partner by providing high-quality sequencing data and expertise.
- Penetration into the Forensic Science Market: The research and development agreement with the FBI provides a pathway for ATLN to penetrate the forensic science market. Direct RNA sequencing using the tSMS platform has the potential to revolutionize forensic analysis by providing more accurate and reliable results. Securing contracts with law enforcement agencies can generate significant revenue and enhance ATLN's reputation.
- Geographic Expansion into International Markets: Expanding the company's presence into international markets, particularly in Europe and Asia, can drive significant growth. These regions are experiencing increasing demand for advanced sequencing technologies. Establishing partnerships with local distributors and research institutions can facilitate market entry and accelerate adoption of the tSMS platform.
- Development of Novel Intellectual Property: Investing in research and development to develop new applications and enhancements for the tSMS platform is crucial for maintaining a competitive edge. This includes exploring new sequencing methods, improving data analysis algorithms, and expanding the platform's capabilities to analyze other types of biomolecules. Continuous innovation will drive long-term growth and create new revenue opportunities.
Opportunities
- Expansion into diagnostic assay development.
- Strategic partnerships with pharmaceutical companies.
- Penetration into the forensic science market.
- Geographic expansion into international markets.
Threats
- Competition from established players in the sequencing market.
- Technological advancements that could render the tSMS platform obsolete.
- Regulatory hurdles for diagnostic assay development.
- Economic downturn that could reduce research funding.
Competitive Advantages
- Proprietary True Single Molecule Sequencing (tSMS) technology platform.
- Strong intellectual property portfolio with patents covering the tSMS technology.
- Established relationships with leading research institutions and pharmaceutical companies.
- Expertise in single-molecule sequencing and data analysis.
About
Founded in 2013 and headquartered in Billerica, Massachusetts, Atlantic International Corp., formerly known as SeqLL Inc., underwent a transformative reverse merger with Lyneer Investments, LLC, on June 18, 2024. This strategic move positioned Atlantic International Corp. as a prominent life sciences instrumentation and research services company. The company is dedicated to the development of scientific assets and novel intellectual property within the omics fields. At the core of its offerings is the True Single Molecule Sequencing technology (tSMS) platform, a cutting-edge solution for DNA and RNA sequencing. This platform empowers researchers to analyze billions of single molecules in a single experiment, generating accurate and reproducible data, which is crucial for advancing scientific understanding and medical breakthroughs. Atlantic International Corp. serves a diverse clientele, including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. These solutions cater to various applications, such as biomarker discovery and diagnostic assay developments. The company also has research and development agreements with the U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform, and the Weizmann Institute of Science for developed and applied innovative single-molecule technologies.
What They Do
- Develops and commercializes the True Single Molecule Sequencing (tSMS) technology platform.
- Provides single-molecule solutions for DNA and RNA sequencing.
- Offers research services to analyze billions of single molecules in a single experiment.
- Generates accurate and reproducible data for biomarker discovery.
- Supports diagnostic assay development for various diseases.
- Collaborates with universities, research centers, and pharmaceutical companies.
- Partners with government institutions like the FBI for forensic applications.
Business Model
- Sells and leases tSMS instrumentation to research institutions and pharmaceutical companies.
- Provides sequencing services to customers who outsource their DNA and RNA analysis.
- Generates revenue from diagnostic assay development and commercialization.
- Forms strategic partnerships with pharmaceutical companies for drug discovery and development.
Industry Context
Atlantic International Corp. operates within the dynamic medical diagnostics and research industry, which is experiencing rapid growth driven by advancements in genomics and personalized medicine. The market for DNA sequencing is projected to reach billions of dollars in the coming years, fueled by increasing demand for biomarker discovery and diagnostic assay development. The competitive landscape includes companies like AVR, CYBN, IMDX, MIST, and NKTX, each vying for market share with varying sequencing technologies. Atlantic International Corp.'s tSMS platform positions it as a key player in the single-molecule sequencing segment, offering unique advantages in accuracy and reproducibility.
Key Customers
- Universities and academic research institutions.
- Biotechnology and pharmaceutical companies.
- Government research institutions.
- Forensic science laboratories.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $110M | -$11M | $-0.20 |
| Q2 2025 | $103M | -$11M | $-0.20 |
| Q1 2025 | $103M | -$11M | $-0.20 |
| Q4 2024 | $130M | -$69M | $-1.29 |
Source: Company filings
Chart & Info
Price Chart
Atlantic International Corp. (ATLN) stock price: $1.90 (-0.14, -6.86%)
Why Bull
- •Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its potential.
- •Community sentiment has shifted positively, with discussions highlighting the company's innovative strategies and growth prospects.
- •Recent partnerships and collaborations have generated buzz, signaling a strong market presence and potential for expansion.
- •Analysts have noted improvements in operational efficiency, which could lead to better profit margins moving forward.
Why Bear
- •Concerns over regulatory challenges have surfaced, casting doubt on the company's ability to navigate compliance issues effectively.
- •Social sentiment has shown some skepticism, with discussions reflecting worries about the company's competitive positioning in a crowded market.
- •Recent earnings reports have not met expectations, leading to a bearish outlook among some investors.
- •Market perception has been impacted by broader economic uncertainties, causing hesitation among potential investors.
Latest News
-
12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga · Jan 26, 2026
-
Why Baker Hughes Shares Are Trading Higher By Around 4%; Here Are 20 Stocks Moving Premarket
benzinga · Jan 26, 2026
-
12 Health Care Stocks Moving In Friday's After-Market Session
benzinga · Jan 23, 2026
-
Atlantic Buys Europe's Circle8 To Create $1.2 Billion Global Hiring Giant
benzinga · Jan 23, 2026
Technical Analysis
Rationale
AI-generated technical analysis for ATLN including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Atlantic International Corp. (ATLN) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for ATLN.
Make a Prediction
Set your price target for Atlantic International Corp. (ATLN), choose a timeframe, and track your prediction accuracy.
Current price: $1.90
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATLN.
Price Targets
Wall Street price target analysis for ATLN.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 4/100
Revenue grew only 10.3% YoY, suggesting the company is in a slower growth phase.
-
Gross Margin 3/100
Gross margin of 10.9% is below average, suggesting thin margins and potential pricing pressure.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Limited cash of $1M could constrain flexibility; watch for dilution risk or debt issuance.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 10/100
Daily turnover of 0.80% indicates healthy liquidity with smooth entry/exit for investors.
-
Price Momentum 6/100
Mixed technical signals (above sma50, above sma200); price trend is inconclusive and may consolidate.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates ATLN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
12 Health Care Stocks Moving In Monday's Pre-Market Session
Why Baker Hughes Shares Are Trading Higher By Around 4%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Friday's After-Market Session
Atlantic Buys Europe's Circle8 To Create $1.2 Billion Global Hiring Giant
Frequently Asked Questions
What does Atlantic International Corp. do?
Atlantic International Corp. is a life sciences instrumentation and research services company that specializes in single-molecule DNA and RNA sequencing. The company's core offering is its True Single Molecule Sequencing (tSMS) technology platform, which provides researchers with a powerful tool for analyzing billions of single molecules in a single experiment. This technology is used for biomarker discovery, diagnostic assay development, and other applications in the fields of genomics and personalized medicine. ATLN serves a diverse customer base, including universities, research centers, pharmaceutical companies, and government institutions.
Is ATLN stock a good buy?
ATLN stock presents a high-risk, high-reward investment opportunity. The company's proprietary tSMS technology offers a unique advantage in the sequencing market, but it faces competition from larger, more established players. With a market capitalization of $0.22 billion, ATLN has significant growth potential if it can successfully commercialize its technology and expand its market share. However, the company's negative profit margin and high beta indicate that it is a speculative investment. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in ATLN.
What are the main risks for ATLN?
The main risks for Atlantic International Corp. include competition from established players in the sequencing market, technological advancements that could render the tSMS platform obsolete, regulatory hurdles for diagnostic assay development, dependence on research funding and grants, and high volatility in the stock price. The company's limited financial resources compared to larger competitors also pose a risk. Additionally, any setbacks in the research and development agreements with the FBI and Weizmann Institute of Science could negatively impact the company's prospects.
Is ATLN a good stock to buy?
Whether ATLN is a good investment depends on your financial goals, risk tolerance, and investment horizon. Review the Investment Thesis, SWOT analysis, and Risk sections on this page. Always do your own research and consult a financial advisor before investing.
What is the ATLN MoonshotScore?
MoonshotScore is our proprietary AI-powered rating system that evaluates stocks based on growth potential, financial health, market momentum, and risk factors. It helps investors quickly identify high-potential opportunities. Check the MoonshotScore badge on this page for the current rating.
How often is ATLN data updated?
Stock prices are updated in real-time during market hours (9:30 AM - 4:00 PM ET). Company fundamentals, analyst ratings, and AI insights are refreshed daily. News is updated continuously throughout the day.
What are the growth catalysts for ATLN?
Growth catalysts vary by company and may include new product launches, market expansion, earnings surprises, partnerships, or industry tailwinds. Check the Catalysts section on this page for specific drivers relevant to Atlantic International Corp..
Who are ATLN's main competitors?
Atlantic International Corp.'s competitors depend on its industry and market segments. Check the Competitors section on this page for a list of direct competitors and how ATLN compares.
What do analysts say about ATLN?
Analyst ratings and price targets for ATLN are aggregated from multiple sources. Check the Analyst Consensus tab for buy/hold/sell ratings and the current consensus price target.
What is ATLN's market cap?
Market capitalization reflects the total market value of ATLN's outstanding shares. Check the Key Statistics section at the top of this page for the current market cap and other key financial metrics.
How has ATLN stock performed recently?
Check the Chart & Info tab for ATLN's recent price action, including daily, weekly, and monthly performance charts with technical indicators.
What are the risks of investing in ATLN?
Every stock carries risk. Check the Risks and Weaknesses sections on this page for ATLN-specific risk factors. Consider macroeconomic conditions, industry trends, and company-specific challenges.
Are insiders buying or selling ATLN?
Insider activity can signal management confidence. Check the Insider Flow tab for recent insider buys, sells, and exercise transactions for ATLN.
Is ATLN a good stock for beginners?
Atlantic International Corp. (ATLN) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is ATLN for first-time investors?
Every stock carries risk, including Atlantic International Corp. (ATLN). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like ATLN.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is limited and may not be fully comprehensive.
- Forward-looking statements are subject to risks and uncertainties.